Acadian Asset Management LLC Reduces Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Acadian Asset Management LLC cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 10.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 466,314 shares of the specialty pharmaceutical company’s stock after selling 55,964 shares during the period. Acadian Asset Management LLC owned approximately 0.82% of Jazz Pharmaceuticals worth $69,611,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MUFG Americas Holdings Corp acquired a new position in Jazz Pharmaceuticals in the 3rd quarter worth $29,000. AdvisorNet Financial Inc purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $37,000. CWM LLC increased its position in shares of Jazz Pharmaceuticals by 156.3% during the third quarter. CWM LLC now owns 323 shares of the specialty pharmaceutical company’s stock worth $41,000 after acquiring an additional 197 shares during the last quarter. Trustcore Financial Services LLC increased its position in shares of Jazz Pharmaceuticals by 52.6% during the fourth quarter. Trustcore Financial Services LLC now owns 290 shares of the specialty pharmaceutical company’s stock worth $43,000 after acquiring an additional 100 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of Jazz Pharmaceuticals by 966.7% in the fourth quarter. Quadrant Capital Group LLC now owns 384 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 348 shares in the last quarter. Hedge funds and other institutional investors own 89.15% of the company’s stock.

A number of brokerages recently commented on JAZZ. BidaskClub lowered Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, February 6th. TheStreet raised Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, November 29th. SunTrust Banks reaffirmed a “buy” rating and issued a target price (up from ) on shares of Jazz Pharmaceuticals in a research report on Friday, January 31st. ValuEngine cut Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 15th. Finally, Wells Fargo & Co raised their price target on shares of Jazz Pharmaceuticals from $186.00 to $189.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. Jazz Pharmaceuticals presently has an average rating of “Hold” and an average price target of $166.14.

Shares of NASDAQ JAZZ opened at $140.85 on Friday. The stock’s 50 day moving average price is $146.52 and its two-hundred day moving average price is $137.40. Jazz Pharmaceuticals PLC has a 52-week low of $116.52 and a 52-week high of $154.24. The stock has a market capitalization of $7.97 billion, a P/E ratio of 13.48, a PEG ratio of 0.76 and a beta of 1.18. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56.

In related news, CEO Bruce C. Cozadd sold 10,750 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $150.00, for a total transaction of $1,612,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Michael Patrick Miller sold 1,500 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $142.18, for a total value of $213,270.00. Following the transaction, the executive vice president now owns 26,571 shares in the company, valued at $3,777,864.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,999 shares of company stock valued at $3,714,896. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: New Google Finance Tool and Screening Stocks

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.